NasdaqCM - Nasdaq Real Time Price USD

Plus Therapeutics, Inc. (PSTV)

1.0801

+0.0901

(+9.19%)

As of 3:04:50 PM EST. Market Open.

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for PSTV

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis

CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates

ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates

OSTX OS Therapies Incorporated

3.8700

-1.02%

QNRX Quoin Pharmaceuticals, Ltd.

0.5705

-11.80%

ZVSA ZyVersa Therapeutics, Inc.

1.1700

-5.65%

MTVA MetaVia Inc.

1.6800

-4.62%

PHIO Phio Pharmaceuticals Corp.

1.7226

-1.00%

XBIO Xenetic Biosciences, Inc.

4.2400

+3.41%

PCSA Processa Pharmaceuticals, Inc.

0.8500

-9.84%

SPRC SciSparc Ltd.

0.2167

+1.40%

PTIX Protagenic Therapeutics, Inc.

0.6149

-5.40%

AFMD Affimed N.V.

1.1750

-0.42%